WC
NBIX icon

Wexford Capital’s Neurocrine Biosciences NBIX Stock Holding History

Wexford Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,089
Closed -$120K – 294
2025
Q1 		$120K Buy
+1,089
New +$138K 0.03% 195
2017
Q3 		– Sell
-7,800
Closed -$359K – 178
2017
Q2 		$359K Buy
+7,800
New +$378K 0.03% 131
2016
Q3 		– Sell
-27,020
Closed -$1.23M – 179
2016
Q2 		$1.23M Hold
27,020
– – 0.21% 67
2016
Q1 		$1.07M Buy
+27,020
New +$1.07M 0.21% 72

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return